Tags

Type your tag names separated by a space and hit enter

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Osteoporos Int. 2019 Mar; 30(3):667-673.OI

Abstract

Early PINP changes correlate with 18-month lumbar spine BMD changes and the correlation was greater with abaloparatide versus teriparatide. The uncoupling index was similar between the two agents.

INTRODUCTION

We evaluated the relationship between early PINP changes and subsequent changes in spine BMD following abaloparatide and teriparatide treatments. We also explored the use of an "uncoupling index" (UI), the balance between bone formation and bone resorption, which we hypothesised would be similar in response to these treatment groups.

METHODS

Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study. BMD was measured by DXA at baseline, 6, 12, and 18 months. Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months. A UI was calculated using log transformation and subtraction of the standard deviate for s-CTX from the standard deviate for s-PINP for each patient.

RESULTS

Early BTM changes were associated with subsequent BMD changes for both treatments. Pearson correlations for the log ratio of PINP over baseline at 3 months and BMD percent change from baseline at 18 months were larger (P < 0.0001) with abaloparatide (r = 0.561) than teriparatide (r = 0.198). The mean UI at 1 month was greater for abaloparatide versus teriparatide (1.743 and 1.493, respectively; P = 0.03) but was similar at 3 months or later time points.

CONCLUSIONS

Early s-PINP changes correlate with percentage change in lumbar spine BMD 18 months after treatment with both abaloparatide and teriparatide, though the correlation with abaloparatide was greater. The UI was similar between abaloparatide and teriparatide suggesting that the balance between formation and resorption markers was similar.

Authors+Show Affiliations

Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK. r.eastell@sheffield.ac.uk.Radius Health, Inc., Waltham, MA, USA.Radius Health, Inc., Waltham, MA, USA.Radius Health, Inc., Waltham, MA, USA.Radius Health, Inc., Waltham, MA, USA.University of California, San Francisco, CA, USA.

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

30635696

Citation

Eastell, R, et al. "Bone Turnover Markers to Explain Changes in Lumbar Spine BMD With Abaloparatide and Teriparatide: Results From ACTIVE." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 30, no. 3, 2019, pp. 667-673.
Eastell R, Mitlak BH, Wang Y, et al. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporos Int. 2019;30(3):667-673.
Eastell, R., Mitlak, B. H., Wang, Y., Hu, M., Fitzpatrick, L. A., & Black, D. M. (2019). Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 30(3), 667-673. https://doi.org/10.1007/s00198-018-04819-1
Eastell R, et al. Bone Turnover Markers to Explain Changes in Lumbar Spine BMD With Abaloparatide and Teriparatide: Results From ACTIVE. Osteoporos Int. 2019;30(3):667-673. PubMed PMID: 30635696.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. AU - Eastell,R, AU - Mitlak,B H, AU - Wang,Y, AU - Hu,M, AU - Fitzpatrick,L A, AU - Black,D M, Y1 - 2019/01/11/ PY - 2018/08/29/received PY - 2018/12/05/accepted PY - 2019/1/13/pubmed PY - 2019/8/20/medline PY - 2019/1/13/entrez KW - Abaloparatide KW - Bone mineral density KW - Bone turnover markers KW - Procollagen type I N propeptide KW - Teriparatide KW - Uncoupling index SP - 667 EP - 673 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 30 IS - 3 N2 - : Early PINP changes correlate with 18-month lumbar spine BMD changes and the correlation was greater with abaloparatide versus teriparatide. The uncoupling index was similar between the two agents. INTRODUCTION: We evaluated the relationship between early PINP changes and subsequent changes in spine BMD following abaloparatide and teriparatide treatments. We also explored the use of an "uncoupling index" (UI), the balance between bone formation and bone resorption, which we hypothesised would be similar in response to these treatment groups. METHODS: Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study. BMD was measured by DXA at baseline, 6, 12, and 18 months. Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months. A UI was calculated using log transformation and subtraction of the standard deviate for s-CTX from the standard deviate for s-PINP for each patient. RESULTS: Early BTM changes were associated with subsequent BMD changes for both treatments. Pearson correlations for the log ratio of PINP over baseline at 3 months and BMD percent change from baseline at 18 months were larger (P < 0.0001) with abaloparatide (r = 0.561) than teriparatide (r = 0.198). The mean UI at 1 month was greater for abaloparatide versus teriparatide (1.743 and 1.493, respectively; P = 0.03) but was similar at 3 months or later time points. CONCLUSIONS: Early s-PINP changes correlate with percentage change in lumbar spine BMD 18 months after treatment with both abaloparatide and teriparatide, though the correlation with abaloparatide was greater. The UI was similar between abaloparatide and teriparatide suggesting that the balance between formation and resorption markers was similar. SN - 1433-2965 UR - https://www.unboundmedicine.com/medline/citation/30635696/Bone_turnover_markers_to_explain_changes_in_lumbar_spine_BMD_with_abaloparatide_and_teriparatide:_results_from_ACTIVE_ DB - PRIME DP - Unbound Medicine ER -